I recently sequenced some bisulfite converted DNA and some unconverted DNA in the same lane of a MiSeq. In the bisulfite converted DNA I had spiked in a small amount of unmethylated lambda DNA as a control. In the unconverted DNA I did not spike in the lambda control. I mapped both the unconverted and converted DNA to the lambda genome with stringent mapping parameters using Bismark. Both samples gave me alignments. It appears that the unconverted sample mapped only to the unconverted lambda genome where as the converted samples mapped to converted lambda genomes. However, how can I confidently determine my conversion efficiency if the results could be due to nonspecific mapping? Has anyone had this problem?
-
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing... -
The immune system’s power comes from its genetic diversity, allowing myriad threats to be neutralized through first recognizing foreign antigens. That diversity is also what makes the immune system so difficult to study. Recent advances in sequencing technology and computational biology, however, are giving researchers new tools to understand immune responses and immune-related diseases in greater detail.
This convergence of genetics, immunology, and computation...09-01-2026, 05:41 AM
